Investment and strategic partnerships are the lifeblood of innovation in healthcare, driving groundbreaking discoveries and accelerating the development of life-changing therapies.
Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology”
Netherlands-based investment group Gilde Healthcare has finally closed its new Venture & Growth VI fund with committed funding of €740 million, well ahead of its origi
The future of public health is set to become increasingly digital, with technological advancements enabling healthcare players to provide more targeted and effective interventions to patien
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl